Bridgebio Pharma
BridgeBio Pharma Inc is an American commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers. The company discovers, develops, and commercializes targeted small molecules, gene therapies, and biologics, including acoramidis for transthyretin amyloidosis. Main revenue drivers include commercial drug sales, strategic biopharmaceutical partnership milestones, and licensing agreements. BridgeBio Pharma serves rare disease patients, clinical research centers, and specialized healthcare providers across North America and international markets. The company holds a prominent position in precision biopharmaceutical development for rare genetic disorders. Headquartered in Palo Alto, California, BridgeBio Pharma Inc is listed on the Nasdaq Stock Market.
14 of the funds FundTelligence covers report a position in Bridgebio Pharma.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 14
Funds holding Bridgebio Pharma
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 4.5 % (partially disclosed portfolio, September 2026)
- Polar Capital Healthcare Discovery Fund — Polar Capital · 4.4 % (largest positions only, October 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.76 % (largest positions only, September 2026)
- DNB Bioteknologi — DNB · 2.74 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 2.53 % (full portfolio disclosed, September 2026)
- Arctic Aurora LifeScience — Arctic · 2.5 % (largest positions only, October 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 1.4 % (partially disclosed portfolio, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.96 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 14 funds holding it.